DGX Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 8.3% compared to Quest Diagnostics's net margin of 5.4%. Quest Diagnostics's return on equity of 13.14% beat Delcath Systems's return on equity of -40.28%.

Quest Diagnostics has a consensus price target of $184.10, signalling upside risk potential of 10.22%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 114.03%. Given that Delcath Systems has higher upside potential than Quest Diagnostics, analysts believe Delcath Systems is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.492, which suggesting that the stock is 50.805% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.871, suggesting its less volatile than the S&P 500 by 12.874%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.86%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Delcath Systems quarterly revenues of $19.8M. Quest Diagnostics's net income of $220M is higher than Delcath Systems's net income of $1.1M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.12x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.87x versus 6.91x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Danaher has a net margin of 8.3% compared to Quest Diagnostics's net margin of 16.62%. Quest Diagnostics's return on equity of 13.14% beat Danaher's return on equity of 7.38%.

Quest Diagnostics has a consensus price target of $184.10, signalling upside risk potential of 10.22%. On the other hand Danaher has an analysts' consensus of $248.27 which suggests that it could grow by 28.44%. Given that Danaher has higher upside potential than Quest Diagnostics, analysts believe Danaher is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.492, which suggesting that the stock is 50.805% less volatile than S&P 500. In comparison Danaher has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.82%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.86%. Danaher offers a yield of 0.61% to investors and pays a quarterly dividend of $0.32 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Danaher quarterly revenues of $5.7B. Quest Diagnostics's net income of $220M is lower than Danaher's net income of $954M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.12x while Danaher's PE ratio is 37.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.87x versus 5.93x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health has a net margin of 8.3% compared to Quest Diagnostics's net margin of -46.77%. Quest Diagnostics's return on equity of 13.14% beat Guardant Health's return on equity of -8518.58%.

Quest Diagnostics has a consensus price target of $184.10, signalling upside risk potential of 10.22%. On the other hand Guardant Health has an analysts' consensus of $59.67 which suggests that it could grow by 24.82%. Given that Guardant Health has higher upside potential than Quest Diagnostics, analysts believe Guardant Health is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.492, which suggesting that the stock is 50.805% less volatile than S&P 500. In comparison Guardant Health has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.2%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.86%. Guardant Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Guardant Health pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Guardant Health quarterly revenues of $203.5M. Quest Diagnostics's net income of $220M is higher than Guardant Health's net income of -$95.2M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.12x while Guardant Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.87x versus 7.62x for Guardant Health. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 8.3% compared to Quest Diagnostics's net margin of 6.36%. Quest Diagnostics's return on equity of 13.14% beat Labcorp Holdings's return on equity of 9.01%.

Quest Diagnostics has a consensus price target of $184.10, signalling upside risk potential of 10.22%. On the other hand Labcorp Holdings has an analysts' consensus of $279.06 which suggests that it could grow by 13.45%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.492, which suggesting that the stock is 50.805% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.086%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.86%. Labcorp Holdings offers a yield of 1.17% to investors and pays a quarterly dividend of $0.72 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Quest Diagnostics's net income of $220M is higher than Labcorp Holdings's net income of $212.8M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.12x while Labcorp Holdings's PE ratio is 28.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.87x versus 1.57x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.